Clinical trial · no report yet · Phase 3
MITHRIDATE
MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera
- NCT04116502 ↗
- Recruiting
- University of Birmingham
- 9 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 4 | |
| Podcasts | 4 | |
| X threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase III, Randomised, Open-label, Multicenter International Trial Comparing Ruxolitinib With Either HydRoxycarbamIDe or Interferon Alpha as First Line ThErapy for High Risk Polycythemia Vera
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Polycythemia Vera
- Interventions
- Ruxolitinib; Hydroxycarbamide; Interferon-Alpha
- Arms
- A- Ruxolitinib · Experimental
- B- Hydroxycarbamide OR Interferon A · Active comparator
- Enrollment
- 586 (estimated)
- Primary outcomes
- Event Free Survival (EFS)
- Sponsor
- University of Birmingham with Novartis, MPN Voice, National Cancer Institute, France
- Start
- Oct 25, 2019
- Primary completion
- Oct 31, 2028 (estimated)
- Results posted
- No
- Registry record
- NCT04116502 · updated Apr 28, 2026